Institut Gustave Roussy

Villejuif, Île-de-France Region 98405

5 studies enrolling now · 18 studies all time

What they study most

ALK-positive Non-small Cell Lung Cancer (NSCLC), Acute Myelogenous Leukemia, Acute Myeloid Leukemia, Advanced Breast Cancer, Advanced Lung Cancer, Advanced or Metastatic Solid Tumors Irrespective of Gene Alterations, Advanced or Metastatic Solid Tumors With Germline PTEN Inactivating Mutations, Bone Marrow Disease, Cancer, Carcinoid Tumor of the Small Bowel, Chronic Lymphocytic Leukemia, Diffuse Large B-cell Lymphoma

Studies at this site

• Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers — Recruiting now
• Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors — Recruiting now
• CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer. — Recruiting now
• Expanded Access Program of Neladalkib (NVL-655) for Patients With Advanced ALK+ NSCLC or Other ALK+ Solid Tumors — Available (expanded access)
• A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study — Running, not enrolling
• Expanded Access Program of Zidesamtinib (NVL-520) for Patients With Advanced ROS1+ NSCLC or Other ROS1+ Solid Tumors — Available (expanded access)
• A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies — Completed
• Study to Investigate the Safety and Tolerability of Odronextamab in Patients With CD20+ B-Cell Malignancies — Completed
• DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing or -Mutated Non-Small Cell Lung Cancer — Stopped early
• MCLA-117 in Acute Myelogenous Leukemia — Stopped early
• TAS-117 in Patients With Advanced Solid Tumors Harboring Germline PTEN Mutations — Stopped early
• Phase 3 Study to Treat Patients With Soft Tissue Sarcomas — Completed
• Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous or Endometrioid Ovarian Cancer (ARIEL3) — Completed
• TAK-659 in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) — Stopped early
• A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours — Completed
• Study of Cryoablation for Metastatic Lung Tumors — Completed
• Multicenter Study of Rociletinib Administered to Patients With Previously Treated Mutant EGFR Non-small Cell Lung Cancer — Stopped early
• Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer — Completed